Argenx price target raised to $717 from $670 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Argenx (ARGX) to $717 from $670 and keeps a Buy rating on the shares. The firm says the “impressive” Q4 performance solidifies Vyvgart’s leadership in the FcRn space with strength in multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Citing the “robust performance” in 2024, H.C. Wainwright raised its 2025 revenue estimate to $3B. Vyvgart has delivered a 134% annual growth since its launch, the analyst tells investors in a research note.